Revenue Recognition (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Cara Therapeutics, Inc.

Schedule of disaggregation of revenue

	Three Months Ended March 31,
	2025		2024
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	1,198	$	788
Total collaborative revenue	$	1,198	$	788
Commercial supply revenue
CSL Vifor (KORSUVA injection)	$	—	$	640
Total commercial supply revenue	$	—	$	640
Clinical compound revenue
Maruishi	$	48	$	84
Total clinical compound revenue	$	48	$	84
Other revenue (non-cash)
CSL Vifor (Kapruvia ex-U.S.)	$	373	$	290
Maruishi		950		333
Total other revenue	$	1,323	$	623

	Year Ended December 31,
	2024		2023		2022
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	2,086	$	12,397	$	16,572
Maruishi		—		539		—
Total collaborative revenue	$	2,086	$	12,936	$	16,572
Commercial supply revenue
CSL Vifor* (KORSUVA injection)	$	640	$	5,843	$	10,223
Total commercial supply revenue	$	640	$	5,843	$	10,223
License and milestone fees
CSL Vifor*	$	—	$	—	$	15,000
Maruishi		—		910		—
Total license and milestone fees	$	—	$	910	$	15,000
Royalty revenue
CSL Vifor (Kapruvia ex U.S.)	$	—	$	415	$	72
Total royalty revenue	$	—	$	415	$	72
Clinical compound revenue
Maruishi	$	84	$	165	$	—
Total clinical compound revenue	$	84	$	165	$	—
Other revenue (non-cash)
CSL Vifor (Kapruvia ex U.S.)	$	1,492	$	284	$	—
Maruishi		2,835		415		—
Total other revenue	$	4,327	$	699	$	—

* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.